Equities

hVIVO PLC

HVO:LSE

hVIVO PLC

Health CareHealth Care Providers
  • Price (GBX)28.35
  • Today's Change-0.50 / -1.73%
  • Shares traded621.42k
  • 1 Year change41.40%
  • Beta1.0942
Data delayed at least 20 minutes, as of Sep 27 2024 16:27 BST.
More ▼

Profile data is unavailable for this security.

About the company

hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It operates through medical and scientific research services segment. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 11+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services. It offers additional clinical field trial services, such as Challenge Models, Pre-clinical, CMC & PK, Study Design & Protocol Development, Ethics & Regulatory, Phase I & II, Volunteer/Patient Recruitment, Clinical site, Monitoring, Biometrics, and Medical Writing. Its subsidiaries include hVIVO Holdings Limited, Open Orphan DAC, hVIVO Inc., and others.

  • Revenue in GBP (TTM)64.38m
  • Net income in GBP17.45m
  • Incorporated2011
  • Employees274.00
  • Location
    hVIVO PLC42 New RoadLONDON E1 2AXUnited KingdomGBR
  • Phone+44 28 9073 7900
  • Websitehttps://hvivo.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Poolbeg Pharma PLC0.00-4.38m52.33m8.0052.33m8.00
Futura Medical PLC8.40m-3.75m108.36m12.00108.36m12.00
Scancell Holdings Plc0.00-5.86m150.03m61.00150.03m61.00
4Basebio PLC506.00k-7.67m176.68m--176.68m--
Allergy Therapeutics plc53.26m-50.22m188.82m635.00188.82m635.00
Bioventix PLC13.60m8.67m192.74m16.00192.74m16.00
hVIVO PLC64.38m17.45m195.72m274.00195.72m274.00
Faron Pharmaceuticals Oy0.00-26.39m232.77m34.00232.77m34.00
Avacta Group Plc23.25m-24.95m247.97m154.00247.97m154.00
Puretech Health PLC349.96k-61.67m342.97m90.00342.97m90.00
Oxford BioMedica plc97.28m-142.02m363.22m834.00363.22m834.00
Data as of Sep 27 2024. Currency figures normalised to hVIVO PLC's reporting currency: UK Pound GBX

Institutional shareholders

26.29%Per cent of shares held by top holders
HolderShares% Held
Octopus Investments Ltd.as of 13 Sep 202468.88m10.12%
JPMorgan Asset Management (UK) Ltd.as of 31 Mar 202447.89m7.04%
Canaccord Genuity Wealth Ltd.as of 30 Apr 202427.10m3.98%
Sterling Investments Management Ltd.as of 31 Oct 20229.97m1.47%
Liontrust Investment Partners LLPas of 31 Jul 20249.37m1.38%
Janus Henderson Investors UK Ltd.as of 30 Jun 20248.62m1.27%
Mandarine Gestion SAas of 29 Feb 20244.27m0.63%
River Global Investors LLPas of 31 Jul 20241.06m0.16%
Lazard Asset Management LLCas of 30 Jun 2024862.12k0.13%
Border to Coast Pensions Partnership Ltd.as of 31 Mar 2024841.70k0.12%
More ▼
Data from 31 Oct 2022 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.